Targeting reactive oxygen species in development and progression of pancreatic cancer

Nisha Durand, Peter Storz

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDA) is characterized by expression of oncogenic KRas which drives all aspects of tumorigenesis. Oncogenic KRas induces the formation of reactive oxygen species (ROS) which have been implicated in initiation and progression of PDA. To facilitate tumor promoting levels and to avoid oncogene-induced senescence or cytotoxicity, ROS homeostasis in PDA cells is balanced by additional up-regulation of antioxidant systems. Areas covered: We examine the sources of ROS in PDA, the mechanisms by which ROS homeostasis is maintained, and the biological consequences of ROS in PDA. Additionally, we discuss the potential mechanisms for targeting ROS homoeostasis as a point of therapeutic intervention. An extensive review of the relevant literature as it relates to the topic was conducted using PubMed. Expert commentary: Even though oncogenic mutations in the KRAS gene have been detected in over 95% of human pancreatic adenocarcinoma, targeting its gene product, KRas, has been difficult. The dependency of PDA cells on balancing ROS homeostasis could be an angle for new prevention or treatment strategies. These include use of antioxidants to prevent formation or progression of precancerous lesions, or methods to increase ROS in tumor cells to toxic levels.

Original languageEnglish (US)
Pages (from-to)19-31
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume17
Issue number1
DOIs
StatePublished - Jan 2 2017

Fingerprint

Pancreatic Neoplasms
Reactive Oxygen Species
Adenocarcinoma
Homeostasis
Antioxidants
Gene Targeting
Poisons
Oncogenes
PubMed
Neoplasms
Carcinogenesis
Up-Regulation
Mutation
Genes

Keywords

  • antioxidants
  • KRas
  • mitochondria
  • NOX
  • pancreatic cancer
  • PanIN
  • Reactive oxygen species

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Targeting reactive oxygen species in development and progression of pancreatic cancer. / Durand, Nisha; Storz, Peter.

In: Expert Review of Anticancer Therapy, Vol. 17, No. 1, 02.01.2017, p. 19-31.

Research output: Contribution to journalReview article

@article{0aa5d2aeb810474fa14b4eab7bc39bc9,
title = "Targeting reactive oxygen species in development and progression of pancreatic cancer",
abstract = "Introduction: Pancreatic ductal adenocarcinoma (PDA) is characterized by expression of oncogenic KRas which drives all aspects of tumorigenesis. Oncogenic KRas induces the formation of reactive oxygen species (ROS) which have been implicated in initiation and progression of PDA. To facilitate tumor promoting levels and to avoid oncogene-induced senescence or cytotoxicity, ROS homeostasis in PDA cells is balanced by additional up-regulation of antioxidant systems. Areas covered: We examine the sources of ROS in PDA, the mechanisms by which ROS homeostasis is maintained, and the biological consequences of ROS in PDA. Additionally, we discuss the potential mechanisms for targeting ROS homoeostasis as a point of therapeutic intervention. An extensive review of the relevant literature as it relates to the topic was conducted using PubMed. Expert commentary: Even though oncogenic mutations in the KRAS gene have been detected in over 95{\%} of human pancreatic adenocarcinoma, targeting its gene product, KRas, has been difficult. The dependency of PDA cells on balancing ROS homeostasis could be an angle for new prevention or treatment strategies. These include use of antioxidants to prevent formation or progression of precancerous lesions, or methods to increase ROS in tumor cells to toxic levels.",
keywords = "antioxidants, KRas, mitochondria, NOX, pancreatic cancer, PanIN, Reactive oxygen species",
author = "Nisha Durand and Peter Storz",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/14737140.2017.1261017",
language = "English (US)",
volume = "17",
pages = "19--31",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Targeting reactive oxygen species in development and progression of pancreatic cancer

AU - Durand, Nisha

AU - Storz, Peter

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Introduction: Pancreatic ductal adenocarcinoma (PDA) is characterized by expression of oncogenic KRas which drives all aspects of tumorigenesis. Oncogenic KRas induces the formation of reactive oxygen species (ROS) which have been implicated in initiation and progression of PDA. To facilitate tumor promoting levels and to avoid oncogene-induced senescence or cytotoxicity, ROS homeostasis in PDA cells is balanced by additional up-regulation of antioxidant systems. Areas covered: We examine the sources of ROS in PDA, the mechanisms by which ROS homeostasis is maintained, and the biological consequences of ROS in PDA. Additionally, we discuss the potential mechanisms for targeting ROS homoeostasis as a point of therapeutic intervention. An extensive review of the relevant literature as it relates to the topic was conducted using PubMed. Expert commentary: Even though oncogenic mutations in the KRAS gene have been detected in over 95% of human pancreatic adenocarcinoma, targeting its gene product, KRas, has been difficult. The dependency of PDA cells on balancing ROS homeostasis could be an angle for new prevention or treatment strategies. These include use of antioxidants to prevent formation or progression of precancerous lesions, or methods to increase ROS in tumor cells to toxic levels.

AB - Introduction: Pancreatic ductal adenocarcinoma (PDA) is characterized by expression of oncogenic KRas which drives all aspects of tumorigenesis. Oncogenic KRas induces the formation of reactive oxygen species (ROS) which have been implicated in initiation and progression of PDA. To facilitate tumor promoting levels and to avoid oncogene-induced senescence or cytotoxicity, ROS homeostasis in PDA cells is balanced by additional up-regulation of antioxidant systems. Areas covered: We examine the sources of ROS in PDA, the mechanisms by which ROS homeostasis is maintained, and the biological consequences of ROS in PDA. Additionally, we discuss the potential mechanisms for targeting ROS homoeostasis as a point of therapeutic intervention. An extensive review of the relevant literature as it relates to the topic was conducted using PubMed. Expert commentary: Even though oncogenic mutations in the KRAS gene have been detected in over 95% of human pancreatic adenocarcinoma, targeting its gene product, KRas, has been difficult. The dependency of PDA cells on balancing ROS homeostasis could be an angle for new prevention or treatment strategies. These include use of antioxidants to prevent formation or progression of precancerous lesions, or methods to increase ROS in tumor cells to toxic levels.

KW - antioxidants

KW - KRas

KW - mitochondria

KW - NOX

KW - pancreatic cancer

KW - PanIN

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=85006247025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006247025&partnerID=8YFLogxK

U2 - 10.1080/14737140.2017.1261017

DO - 10.1080/14737140.2017.1261017

M3 - Review article

C2 - 27841037

AN - SCOPUS:85006247025

VL - 17

SP - 19

EP - 31

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -